Publications
- VeriStrat Classifier for Survival and Time To Progression in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Erlotinib and Bevacizumab. Lung Cancer, September 2010, Carbone et al.
- Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503. Journal of Thoracic Oncology, February 2010, Amann et al.
2011 ASCO Abstracts
2010 ASCO Abstracts
2009 ASCO Abstracts
- Mass spectrometry profile as a predictor of overall survival benefit after treatment with epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma.
- Genetic and proteomic features associated with survival after treatment with erlotinib in first line therapy of non-small cell lung cancer.
2008 ASCO Abstracts
- Changes in serum proteomic profile of non-small cell lung cancer (NSCLC) patients during therapy with epidermal growth factor receptor tirosine kinase inhibitors (EGFR-TKIs): Preliminary report.
- Predictive value of serum MALDI-TOF proteomic profiling from patients treated with erlotinib and bevacizumab for survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib alone.